Ruda Slaska buying Ecstasy

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Ruda Slaska buying Ecstasy

This clinical trial focuses on children with high-grade gliomas HGG , which are a type of aggressive brain tumor. HGG represents a significant challenge in pediatric cancer due to poor long-term survival rates despite advances in treatment. The study investigates the use of rapamycin , a drug aimed at blocking a pathway related to tumor growth. The trial will assess the safety and effectiveness of adding rapamycin to standard chemotherapy treatments for children diagnosed with high-grade gliomas. Standard chemotherapy in this study includes drugs like temozolomide and lomustine. A secondary goal is to determine the clinical effectiveness of this combination treatment. The study also explores whether specific genetic markers might influence how well the treatment works. During the trial, participants will be randomly divided into two groups. One group will receive standard chemotherapy, while the other group will receive the same chemotherapy with the addition of rapamycin. The treatment period will last approximately 36 weeks, and rapamycin will be administered daily for about six months. After completing the treatment, children will undergo close monitoring for six months, followed by up to five years of survival observation. The clinical trial aims to study drug-resistant epilepsy in children, which is epilepsy that does not respond to typical medications. The study also focuses on conditions triggered by activity in a specific biological pathway in the body known as the mTOR pathway. The diseases covered by the study include conditions with brain abnormalities such as focal cortical dysplasia an abnormal development of brain tissue , hemimegalencephaly where one hemisphere of the brain is larger than the other , and certain rare tumors. The therapy involves the use of a drug called rapamycin also known as Rapamune , which is taken orally in syrup form. This drug is known to interfere with the mTOR pathway, which is linked to these conditions. The primary goal is to determine the safety and tolerance of rapamycin as an additional treatment to the standard anti-epileptic drugs. As part of the process, some children will receive a combination of standard care and rapamycin, while others will receive only standard care. After certain periods, the treatments will be switched between groups to compare results. The study spans over 9 months for each participant. During this time, several medical evaluations will be conducted, including imaging tests like MRI, laboratory tests, and assessments to monitor quality of life and any side effects related to treatment. Chronic Lymphocytic Leukemia is a type of cancer that affects a specific kind of white blood cells called lymphocytes. Hypogammaglobulinemia is a condition characterized by low levels of antibodies that help fight infections. The therapy being tested is called Panzyga , which is an intravenous immunoglobulin IVIG made from human plasma. The study is designed to evaluate the effectiveness and safety of Panzyga in preventing infections in patients with CLL. The study involves two groups of participants: one group will receive Panzyga, and the other group will receive a placebo. Neither the participants, care providers, nor the researchers will know who is receiving Panzyga and who is receiving the placebo. This method is used to ensure that the results are as unbiased as possible. This study is randomized , meaning participants are randomly assigned to one of the two groups. It is also a Phase III study , which means it focuses on confirming the effectiveness and monitoring the side effects of the treatment in a larger group of people. The primary goal is to see if Panzyga can reduce the occurrence of major infections in CLL patients who have low antibody levels. Participants will be monitored for 52 weeks to track infection rates and any side effects. The study is for patients with non-segmental vitiligo. The aim is to assess the efficacy and safety of the drug povorcitinib in treating this disease. Povorcitinib is administered as oral tablets. The study will use two types of treatment: one group of participants will receive povorcitinib, and the other group will receive a placebo and then povorcitinib. The patient must have a clinically confirmed diagnosis of non-segmental vitiligo. The skin manifestations must involve a significant part of the body, including the face. The patient must agree to stop using all previous treatments for vitiligo during the study. Epidermolysis Bullosa Simplex EBS is a genetic disorder where the skin is very fragile and forms blisters easily, often due to mutations in certain skin proteins keratins 5 and Diacerein has anti-inflammatory properties and works by inhibiting specific inflammation-causing substances in the body. Previous studies have shown that Diacerein can reduce keratin aggregates, which are a key factor in severe EBS. The study is divided into two parts. In Part A , participants will be randomly assigned to receive either the AC ointment or a vehicle ointment an ointment without active ingredients once a day. This part of the study is double-blinded, meaning neither the participants nor the researchers will know who receives which treatment. This helps ensure unbiased results. After completing Part A, participants will move to Part B , an open-label extension phase where everyone will receive the AC ointment once a day. In this phase, both the participants and the researchers will know they are receiving the active treatment. Non-small cell lung cancer NSCLC is a type of lung cancer that generally grows and spreads more slowly than small cell lung cancer. This therapy is being tested both on its own and in combination with another type of treatment known as a PD-1 inhibitor. This is an open-label study, meaning that both the patients and the researchers will know which treatment is being administered. The study will monitor how well the treatments work in shrinking or controlling the cancer and will also keep track of any side effects experienced by patients. This study includes specific criteria for who can participate based on factors like overall health and medical history. The goal is to find a new, effective treatment for NSCLC with fewer side effects, improving the quality of life and survival rates for patients. This clinical trial focuses on metastatic non-small cell lung cancer NSCLC , a type of lung cancer that has spread to other parts of the body. The study aims to determine if the combination of Sacituzumab Tirumotecan and Pembrolizumab improves overall survival OS better than Pembrolizumab alone. One group will receive Sacituzumab Tirumotecan and Pembrolizumab together. Sacituzumab Tirumotecan will be given via intravenous IV infusion on specific days across a 6-week cycle, while Pembrolizumab will be administered every 6 weeks for up to 18 cycles. The other group will receive Pembrolizumab alone, also via IV infusion every 6 weeks for up to 18 cycles. All participants will receive additional medications like diphenhydramine an antihistamine , an H2 antagonist to reduce stomach acid , acetaminophen to reduce fever and pain , and dexamethasone a steroid during the initial infusions to help manage side effects. The study will include regular monitoring and assessments to determine the effectiveness and safety of the treatments. The primary goal is to see if the combination of Sacituzumab Tirumotecan and Pembrolizumab can provide a survival benefit over using Pembrolizumab alone. The disease covered by this study is systemic lupus erythematosus SLE. Participants will receive a therapy called upadacitinib, which is already approved to treat rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The aim of the study is to evaluate the efficacy and safety of upadacitinib in adult patients with moderately to severely active SLE disease. Adverse events and changes in disease activity will be assessed during the study. Each participant will take oral upadacitinib or placebo tablets daily for 52 weeks. The clinical trial is aimed at patients suffering from active systemic lupus erythematosus SLE , an autoimmune disease in which the immune system attacks its own tissues. The study will evaluate the effectiveness and safety of Deucravacitinib compared with placebo. The aim of the study is to evaluate whether Deucravacitinib is effective in reducing disease activity and improving the health of patients with moderate to severe disease. The effectiveness of therapy will be assessed based on several indicators, including overall health, number of active joints, and skin symptoms. The study is aimed at adult patients aged 18 to The condition for participation is the diagnosis of systemic lupus erythematosus confirmed at least 24 weeks before the qualifying visit. The study is aimed at patients at high risk of early-stage TNBC who do not have metastatic disease. During the study, one of the drugs, Adagloxad Simolenin in combination with OBI, will be administered to patients as up to 21 subcutaneous injections over a period of weeks. In comparison, some patients will receive standard treatment without additional investigational drugs. Both groups of patients will visit the research center at the same time intervals. The primary aim of the study is to evaluate whether Adagloxad Simolenin in combination with OBI improves invasive disease-free survival IDFS , which is the time from randomization to the first recurrence of disease, the appearance of a new cancer, or death from any cause. Treatment also includes standard chemotherapy, both preoperatively and postoperatively, which is in line with current guidelines. Both postmenopausal women and those who may still have children can participate in the study, provided they use effective contraceptive methods. The study involves a drug called Dupilumab and targets adults and adolescents with active eosinophilic gastroenteritis. This is a rare chronic immune disease in which eosinophils a type of white blood cell accumulate in large numbers in the stomach and small intestine, causing inflammation and damage. The aim of the study is to evaluate the effect of dupilumab on relieving symptoms of the disease and reducing inflammation in the stomach and small intestine in adults and adolescents. The study consists of three parts, plus a screening and observation part. In Parts A and B, participants will be randomly assigned to a group receiving dupilumab or placebo for 24 weeks in a double-blind neither participants, physicians nor study staff will know which treatment a participant is receiving. Part C is a week extension part, in which all participants from parts A and B will receive dupilumab. The study focuses on patients with gout and hyperuricemia. It aims to evaluate the effectiveness and safety of different doses of the drug Tigulixostat compared to allopurinol. Hyperuricemia is a high level of uric acid in the blood, which can lead to gout attacks, causing painful joint inflammations. Eligible participants are adults aged 18 to 85, both men and women, with high blood uric acid levels and a history or presence of gout. The study will compare three doses of Tigulixostat mg, mg, mg taken once daily for up to 12 months and allopurinol doses ranging from mg to mg, taken three times daily for the same period. The effect of a placebo taken three times daily for up to 6 months will also be evaluated. The primary goal is to assess the number of patients whose blood uric acid levels drop below 6. Additionally, the study will determine how many patients achieve levels below 5. The study will also evaluate the total reduction of gout tophi nodules and the frequency of adverse side effects. WVE is a type of drug designed to target specific genetic sequences. The drug is administered intrathecally, i. The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks. The goal is to collect data on the effectiveness of AMT in sick patients. Participants in this cohort will also receive immunosuppressive therapy consisting of dexamethasone, sirolimus, and rituximab. At the end of the month, 36 visit, participants will be informed about their assigned treatment group. The goal is to further evaluate the safety and effectiveness of low or high dose AMT The study aims to expand the number of patients exposed to two doses to provide a sufficient sample for safety and effectiveness comparisons. Both studies will share a common set of clinical, safety, imaging, and biomarker assessments over 5 years of follow-up. The main objectives of the study include assessing the safety and tolerability of administering AMT to both hemispheres of the brain. The evaluation will include various parameters such as adverse events, changes in blood pressure, respiratory rate, heart rate, electrocardiograms, neurological and physical examinations, as well as laboratory tests such as clinical chemistry, hematology, urinalysis and cerebrospinal fluid analysis. This clinical trial focuses on idiopathic nephrotic syndrome INS , a kidney disorder causing excessive protein loss in the urine, leading to swelling and other complications. The study aims to evaluate the safety and effectiveness of rituximab for children aged 24 months to 16 years with steroid-dependent nephrotic syndrome SDNS or frequently relapsing nephrotic syndrome FRNS. Participants will be randomly assigned to receive either rituximab or a placebo during a double-blind phase lasting up to days. Following this period, all participants will receive rituximab in an open-label extension phase. The study will monitor the time to the first relapse, assess disease progression, and observe any adverse effects. Regular health assessments, including physical exams, blood tests, and monitoring of disease progression, will be conducted throughout the trial to ensure the safety and well-being of the participants. The goal is to determine if rituximab can extend the period of remission and reduce the frequency of relapses in children with INS. This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib. Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection. The aim of this study is to test a new drug combination to treat metastatic uveal melanoma, a type of cancer that starts in the eye and spreads to other parts of the body. The main drugs being tested are IDE also called darovasertib and crizotinib, both taken by mouth twice daily. Currently, this process is divided into several stages. Once they determine the best dose of IDE, they will move to the next step in which everyone will receive that dose along with crizotinib or one of the other treatments. Researchers will primarily look at how long the cancer stays under control without getting worse and how long patients live. It could take about 4 years to get all the answers you need. The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient — this could be another experimental drug, standard therapy, or simply supportive care. Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses. This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Patients will be randomly assigned to receive Rosnilimab or placebo. DASCRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease. This study involves children with kidney diseases that lead to high levels of protein in the urine. The study will use a drug called Sparsentan, administered as an oral suspension or tablet. The goal is to determine if Sparsentan is safe and effective for these children. Participants will receive Sparsentan for weeks, and their progress will be monitored to see if protein levels in their urine decrease and if their overall health improves. The study is open-label, meaning all participants will know they are receiving the drug. Clinical trials Trial search Poland Warsaw. Search by disease. Search by location. Clinical trials located in Warsaw. Warsaw city is located in Poland. Currently, 20 clinical trials are being conducted in this city. Bydgoszcz , Poland. Lublin , Poland. Katowice , Poland. Warsaw , Poland. Szczecin , Poland. Olsztyn , Poland. Krakow , Poland. Gdynia , Poland. Kielce , Poland. Koszalin , Poland. Opole , Poland. Gliwice , Poland. Siedlce , Poland. Bytom , Poland. Sopot , Poland. Sosnowiec , Poland. Zabrze , Poland. Otwock , Poland. Grodzisk Mazowiecki , Poland. Tychy , Poland. Konin , Poland. Malbork , Poland. Skierniewice , Poland. Bystra , Poland. Radom , Poland. Nowy Targ , Poland. Piaseczno , Poland. Legnica , Poland. Sochaczew , Poland. Wadowice , Poland. Chojnice , Poland. Prabuty , Poland. Nadarzyn , Poland. Wieliszew , Poland. Zawadzkie , Poland. Ossy , Poland. Rybnik , Poland. Osielsko , Poland. Karczew , Poland. Lubin , Poland. Sztum , Poland. Kobylniki , Poland. Grzepnica , Poland. Poland , Poland. Trzebnica , Poland. Strzelce Opolskie , Poland. Gryfice , Poland. Leszno , Poland. Wejherowo , Poland. Zgierz , Poland. Skawina , Poland. Clinical study on Chronic Lymphocytic Leukemia and Hypogammaglobulinemia using drugs. Povorcitinib in patients with non-segmental vitiligo. Upadacitinib in the treatment of systemic lupus erythematosus. Deucravacitinib in the treatment of systemic lupus erythematosus SLE. Clinical study on Triple Negative Breast Cancer using drugs. Clinical study on tophi, gout flares, and hyperuricemia using tigulixostat, allopurinol, and placebo. Clinical study on Huntington Disease using drugs. Evaluating Rituximab's efficacy and safety in pediatric Idiopathic Nephrotic Syndrome. Clinical study on Rheumatoid Arthritis using Rosnilimab and placebo. See more clinical trials in other cities in Poland:?